Shanghai, China – July 22, 2019 – MICRO-TECH successfully listed on the STAR Market (Shanghai Stock Exchange Science and Technology Innovation Board), becoming one of the first 25 companies to debut on the newly launched board.
The listing marks a defining milestone in the company’s growth journey and signals its transition into a new phase of accelerated expansion, innovation, and global market development.
The STAR Market officially commenced trading on 22 July 2019, representing a landmark reform in China’s capital markets aimed at supporting high-growth, innovation-driven companies.
At the opening ceremony, senior Chinese officials including Mr Li Qiang, then Member of the Political Bureau of the CPC Central Committee and Party Secretary of Shanghai, and Mr Yi Huiman, Chairman of the China Securities Regulatory Commission (CSRC), officiated the launch as the first group of companies began trading.
As one of the inaugural listed companies on the STAR Market, and the first from Nanjing, MICRO-TECH debut underscores both its position among China’s leading innovation-driven enterprises and its role in representing a new generation of globally competitive medtech companies.
Strong Market Confidence and Capital Raise
MICRO-TECH issued 33.34 million shares at an offering price of RMB 52.45 per share, raising total proceeds of approximately RMB 1.748 billion (approximately USD 254 million).
The company achieved an oversubscription of RMB 855 million, ranking first among the initial STAR Market listings in terms of excess fundraising, reflecting strong investor confidence in its growth prospects and innovation capabilities.
Stock Name: 南微医学 (“Nanwei Medical”)
Stock Code: 688029
Proceeds from the IPO will be used to support expansion of manufacturing facilities, development of domestic and international R&D and laboratory centers, strengthening of global marketing and distribution networks, and investment in digital and information infrastructure.
From Local Innovator to Global MedTech Player
Founded in 2000, MICRO-TECH has evolved from a single-product manufacturer into a leading player in minimally invasive medical technology, with capabilities spanning three core technology platforms: Endoscopic diagnosis and treatment, tumor ablation, and optical coherence tomography (OCT).
Over two decades, the company has expanded from a primarily domestic business into a dual-engine growth model combining China and international markets, supported by advanced manufacturing systems, a globalizing commercial network, and a growing innovation pipeline.
Accelerated IPO Journey
MICRO-TECH’s listing followed a highly efficient IPO process aligned with the STAR Market’s streamlined regulatory framework:
- June 2018: IPO process initiated
- April 2019: Application accepted by Shanghai Stock Exchange
- June 2019: Approved by the Listing Committee
- July 2019: Registration completed in just 13 days
- 22 July 2019: Official listing on STAR Market
The entire journey from IPO initiation to listing was completed in approximately 396 days, underscoring both regulatory efficiency and the company’s operational readiness.
At the listing agreement ceremony held at the Shanghai Stock Exchange, MICRO-TECH’s Chairman reflected on the significance of the moment: “The STAR Market represents a major step forward in China’s capital market reform and a powerful platform for innovation-driven enterprises,” said Mr Long Xiaohui, Chairman, MICRO-TECH.
“For MICRO-TECH, this is not only a historic milestone, but also a new starting point. With the support of capital markets, we are well positioned to accelerate innovation, expand globally, and contribute meaningfully to the advancement of healthcare.”
He added that the company remains committed to its core philosophy of “integrity in innovation and excellence in craftsmanship,” and will continue to deliver high-quality medical technologies that improve patient outcomes, reduce healthcare costs, and elevate clinical standards worldwide.
As global demand for minimally invasive procedures continues to rise, MICRO-TECH is strategically positioned to benefit from what industry observers describe as a “golden decade” for medical device innovation.
The company’s successful listing on the STAR Market strengthens its ability to accelerate product innovation and clinical development, scale manufacturing and supply chain capabilities, expand into new international markets, and deepen collaboration with global healthcare partners.
The IPO represents not only a corporate milestone, but also a broader contribution to China’s healthcare innovation ecosystem and its integration with global capital markets.
